ALSO NOTED: Korean pharma mired in family feud; Boston Scientific implant gets EU nod;

> Dong-A Pharmaceutical asked Korean authorities to investigate its former chief executive for embezzlement. The nation's top drug maker has been embroiled in a family feud for control for years. Report [1]

> European regulators approved Boston Scientific's new defibrillator known as Confient. Release [2]

> SkyePharma appointed Jeremy Scudamore as non-executive chairman of its board, replacing Jerry Karabelas. Report [3]

> Indian drug maker Cipla and Ugandan partner Quality Chemicals opened a new factory to produce HIV/AIDS meds in the African country. Report [4]

> QLT agreed to take over ForSight Newco, an ocular product company, for $42 million; the deal includes a novel drug-delivery system using "punctal plugs" for a variety of eye conditions. Release [5]

> GlaxoSmithKline is buying into Anacor Pharmaceuticals' research work, inking a deal to in-license boron-containing small molecule anti-infective drug candidates. Report [6]

> Chemistry-related skills are in demand, which is translating to some attractive salaries in the research field. Report [7]

> The Nobel Prize for medicine has gone to three researchers in recognition of their collective work on gene targeting, a process that allows researchers to turn genes off and on in mice. Report [8]

> The market for insomnia drugs in the U.S. is growing at a whopping 29 percent per year, hitting $4.6 billion in 2006 and attracting the attention of a wide range of drug developers. Report [9]

And Finally... Should the FDA allow behind-the-counter drug sales? Poll [10]